<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials</title>
			</titleStmt>
			<publicationStmt>
				<publisher>BMJ</publisher>
				<availability status="unknown"><p>Copyright BMJ</p>
				</availability>
				<date type="published" when="2014-08">2014-08</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Dr</roleName><forename type="first">Sripal</forename><surname>Bangalore</surname></persName>
							<email>sripalbangalore@gmail.com</email>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Amita</forename><surname>Singh</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bora</forename><surname>Toklu</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">J</forename><surname>Dinicolantonio</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kevin</forename><surname>Croce</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frederick</forename><surname>Feit</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deepak</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Singh A</orgName>
								<address>
									<settlement>Bangalore S, Toklu B, et al</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="laboratory">Society of Cardiovascular Patient Care; Chair: American Heart Association Get With The Guidelines Steering Committee; Data Monitoring Committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Belvoir Publications</orgName>
								<orgName type="institution">Boston VA Research Institute</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Invasive Cardiology), Population Health Research Institute</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">The Medicines Company; Unfunded Research: FlowCo</orgName>
								<orgName type="laboratory">American College of Cardiology (Section Editor, Pharmacology); Research Grants: Amarin</orgName>
								<address>
									<addrLine>AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Roche, Sanofi Aventis, PLx Pharma</addrLine>
									<region>Takeda</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Open Heart</title>
						<title level="j" type="abbrev">Open Heart</title>
						<idno type="eISSN">2053-3624</idno>
						<imprint>
							<publisher>BMJ</publisher>
							<biblScope unit="volume">1</biblScope>
							<biblScope unit="issue">1</biblScope>
							<biblScope unit="page">e000068</biblScope>
							<date type="published" when="2014-08" />
						</imprint>
					</monogr>
					<idno type="DOI">10.1136/openhrt-2014-000068</idno>
					<idno type="PMID">25332804</idno>
					<idno type="PMCID">PMC4189225</idno>
					<ptr type="open-access" target="https://openheart.bmj.com/content/1/1/e000068.full.pdf" />
					<note type="submission">Received 19 February 2014 Revised 30 May 2014 Accepted 15 July 2014 For numbered affiliations see end of article.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T01:09+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart 2014;1:e000068.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>Dual antiplatelet therapy (DAPT) with aspirin and an ADP receptor inhibitor is the standard of care for patients undergoing percutaneous coronary intervention (PCI). However, there is significant interindividual variability in the extent of platelet inhibition achieved with clopidogrel. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref> Several studies have shown a correlation between high levels of on-treatment platelet reactivity (HTPR) and adverse cardiovascular outcomes, such that patients with HTPR (also called clopidogrel resistance) have a threefold to fivefold increased risk for recurrent ischaemic events. <ref type="bibr">4 5</ref> Cilostazol, a phosphodiesterase III inhibitor, exhibits its antiplatelet effects via inhibition of the conversion of cyclic AMP (cAMP) to 5'-AMP</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>KEY MESSAGES</head><p>What is already known about this subject? ▸ Cilostazol, a phosphodiesterase III inhibitor, exhibits antiplatelet effect and inhibits neointimal hyperplasia and smooth muscle proliferation. However, its role in addition to dual antiplatelet therapy (DAPT) of aspirin and clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is not well defined.</p><p>What does this study add? ▸ In patients undergoing PCI, addition of cilostazol to DAPT results in decreased platelet reactivity and a significant reduction in cardiovascular outcomes including stent thrombosis, even in the drug-eluting stent era.</p><p>How might this impact on clinical practice? ▸ The current study provides evidence to support use of cilostazol as an attractive and strong competitor for newer antiplatelet regimens and should be evaluated in future trials in patients undergoing PCI.</p><p>causing a subsequent increase in cAMP within platelets, and has been shown to augment platelet inhibition when it is added to aspirin and clopidogrel as part of a triple therapy regimen. <ref type="bibr">6 7</ref> In addition, cilostazol inhibits neointimal hyperplasia and smooth muscle proliferation, and has the potential to reduce the risk of restenosis after coronary stent implantation. <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> Despite these pharmacologic effects, clinical results from observational and small randomised trials have not shown a consistent clinical benefit. Our objective was to evaluate whether triple antiplatelet therapy (TAPT) with cilostazol (in addition to aspirin and clopidogrel) decreases platelet reactivity and reduces adverse cardiovascular (CV) outcomes when compared with a dual antiplatelet (DAPT) regimen of aspirin and clopidogrel alone.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eligibility criteria</head><p>We conducted a MEDLINE, EMBASE and CENTRAL search using the MeSH terms 'cilostazol' and 'randomised clinical trial'. We limited our search to trials involving human subjects through May 2014. The search terms were broad with no language restrictions imposed. We checked the reference lists of review articles and prior meta-analyses to assess for additional eligible studies. Corresponding authors of studies were contacted for further information if relevant data were not reported. Trials in abstract format without a manuscript published were also included in the analysis.</p><p>To be included for analysis, eligible trials had to fulfil the following criteria: (1) randomised clinical trials of TAPT (aspirin, clopidogrel and cilostazol) in comparison to DAPT (aspirin and clopidogrel); (2) enrolment of patients undergoing PCI with drug-eluting or bare metal stents and (3) follow-up of at least 2 weeks for trials reporting platelet reactivity outcomes and at least 1 month for trials reporting cardiovascular outcomes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selection and quality assessment</head><p>Three authors (AS, BT and SB) independently reviewed trial eligibility and quality. Disagreements were resolved by consensus. Risk of bias was assessed using criteria recommended by the Cochrane Collaboration, specifically evaluating sequence generation of allocation; allocation concealment; blinding of participants, staff and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. <ref type="bibr" target="#b11">12</ref> Trials with high or unclear risk of bias for the first three criteria were considered as high bias risk trials and the rest as low bias risk trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data extraction and synthesis</head><p>The primary platelet reactivity outcome was differences in platelet reactivity unit (PRU) after treatment in TAPT versus DAPT groups. Secondary outcomes were percent platelet inhibition and rate of HTPR. We used a cut-off of PRU &gt;235 as the threshold for identifying patients with HTPR who may be at high risk for ischaemic or thrombotic events following PCI, as has been recommended by a recent consensus document. <ref type="bibr" target="#b12">13</ref> Of note, definition of HTPR differed by study.</p><p>Our primary CV outcome was major adverse cardiovascular events (MACE), defined as death, myocardial infarction (MI) or target lesion revascularisation (TLR). We evaluated secondary CV outcomes of death, cardiovascular death, MI, stent thrombosis, TLR and target vessel revascularisation (TVR). Safety outcomes of major bleeding, minor bleeding, any (major or minor) bleeding and drug discontinuation due to adverse effects were also evaluated. The definitions of bleeding varied between the trials. Given the lack of consistent reporting of the Academic Research Consortium definitions of stent thrombosis from the studies, we used the individual trial protocol definitions of stent thrombosis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>We performed an intention to treat meta-analysis in line with recommendations from the Cochrane Collaboration and the PRISMA Statement <ref type="bibr">14 15</ref> and used standard software for statistical analysis (STATA V.9.0, STATA Corp, Texas, USA). Heterogeneity was assessed using the I 2 statistic, defined as the proportion of total variation observed between the trials attributable to differences between trials rather than sampling error (chance), with values &lt;25% considered as low and &gt;75% as high. <ref type="bibr" target="#b15">16</ref> The pooled effect for each grouping of trials was derived from the point estimate for each separate trial weighted by the inverse of the variance (1/SE 2 ). Continuous variable outcomes (PRU, per cent platelet inhibition) between the groups were compared with both a fixed effect model using the inverse variance method and a random effects model using the DerSimonian and Laird method. For cardiovascular outcomes, rates were expressed per patient-years to adjust for the varying duration of follow-up. Results were therefore reported as incident rate ratios (IRR) and 95% CIs with the use of both a fixed effect model using the method of Mantel and Haenszel and a random effects model using the method of DerSimonian and Laird, with the estimate of heterogeneity being taken from the Mantel-Haenszel model. Publication bias was estimated using the weighted regression tests of Begg and Egger. <ref type="bibr" target="#b11">12</ref> For platelet reactivity indices, analyses were stratified based on whether standard-dose (75 mg) or high-dose (150 mg) clopidogrel was used in the DAPT arm. In addition, further sensitivity analyses were performed based on the cohort enrolled: (1) acute coronary syndrome (ACS) versus not; and (2) enrolment of patients with HTPR at baseline versus not. For cardiovascular outcomes, analyses were stratified based on stent typedrug eluting stent (DES) versus Bare metal stent (BMS). A p value of &lt;0.05 was considered significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study selection</head><p>We identified 41 trials that satisfied the inclusion criteria (figure 1). Seventeen trials reported platelet reactivity outcomes of which 10 comparator arms used high dose (150 mg) of clopidogrel. A total of 34 trials reported CV outcomes, the majority (25 trials) of which used DES.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline characteristics</head><p>The baseline characteristics, inclusion criteria and quality assessment are summarised in tables 1-4. In order to quantify platelet reactivity outcomes, we evaluated 17 trials with 20 comparator arms and 5056 patients. The median follow-up was 30 days and although the definition of HTPR was heterogeneous, all trials used the VerifyNow P2Y12 assay to measure platelet reactivity.  <ref type="figure" target="#fig_1">figure 2A</ref>). There was a larger mean difference between the TAPT and DAPT groups when the analysis was restricted to a DAPT group using standard-dose clopidogrel (mean PRU 189.54 vs 255.83) where the PRU value was lower by a mean of 64.10 (95% CI −84.35 to −43.85). Moreover, TAPT was associated with a lower PRU value even when compared with DAPT using high-dose clopidogrel (mean difference of 27.17) (mean PRU 176.27 vs 209.48) (figure 2A). The results were similar when stratified by ACS status (see web appendix figure A1) or by baseline clopidogrel resistance status (see web appendix figure A2). There was moderate-to-high heterogeneity for the above analysis. However, the heterogeneity was reduced in subgroup analysis restricted to comparison with high-dose clopidogrel (figure 2A), in trials enrolling patients with baseline clopidogrel resistance (see web appendix figure A2 and in trials enrolling patients without ACS (see web appendix <ref type="figure" target="#fig_0">figure A1)</ref>.</p><p>In addition, the mean PRU values on treatment in the TAPT group in each of the trials were below a PRU of 235, which has been cited in the literature as the suggested threshold for defining HTPR. <ref type="bibr" target="#b12">13</ref> Secondary outcomes: percent platelet inhibition and high on-treatment platelet reactivity TAPT was associated with a 12.71% greater platelet inhibition compared to DAPT for the overall cohort (95% CI 10.76 to 14.67, p&lt;0.0001) (figure 2B). TAPT was also associated with a greater platelet inhibition in comparison with DAPT using standard-dose clopidogrel (14.37% mean greater platelet inhibition) and remained significant even when compared with DAPT using highdose clopidogrel (9.07% mean greater platelet inhibition) (figure 2B). There was moderate heterogeneity for the above analysis. The results were similar when stratified by ACS status (see web appendix figure A3) or by baseline clopidogrel resistance status (see web appendix figure A4).</p><p>In addition, TAPT was associated with a 60% reduction in the risk of HTPR when compared with DAPT (figure 2C) (relative risk=0.40; 95% CI 0.30 to 0.53, p&lt;0.0001). When stratified by clopidogrel dose, TAPT was associated with a 50% reduction in risk of HTPR compared to standard-dose DAPT and a 72% reduction compared to high-dose DAPT (figure 2C). Heterogeneity was moderate with no evidence for significant publication bias. The results were similar when stratified by ACS status (see web appendix figure A5) or by baseline clopidogrel resistance status (see web appendix figure A6). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cardiovascular outcomes Primary outcome</head><p>TAPT was associated with a 32% reduction in the risk of MACE (IRR=0.68; 95% CI 0.60 to 0.78) when compared with DAPT for the overall cohort (figure 3A). This effect was observed regardless of stent type (P interaction &gt;0.05) such that even in patients undergoing PCI with DES, TAPT resulted in a 36% reduction in MACE   <ref type="figure" target="#fig_3">3C)</ref> for the overall cohort. The IRR was independent of stent type as TAPT showed benefit regardless whether BMS and DES was used (stent type, P interaction &gt;0.05). In the overall cohort, TAPT was associated with a 43% reduction in the risk of TLR (IRR=0.57; 95% CI 0.44 to 0.73) ( <ref type="figure" target="#fig_3">figure 3D</ref>) and a 31% reduction in the risk of TVR (IRR=0.69; 95% CI 0.59 to 0.81) ( <ref type="figure" target="#fig_3">figure 3E</ref>) compared with DAPT. TAPT efficacy for reducing TLR and TVR was present even when the analyses were restricted to studies using DES. In DES-treated patients, TAPT resulted in a 43% reduction in TLR (IRR=0.57; 95% CI 0.44 to 0.74) and a 35% reduction in TVR (IRR=0.65; 95% CI 0.54 to 0.79) with TAPT compared with DAPT.</p><p>TAPT was associated with significantly lower stent thrombosis rate when compared with DAPT (IRR=0.63; 95% CI 0.40 to 0.98) ( <ref type="figure" target="#fig_3">figure 3F</ref>). There was no heterogeneity (0%) in all of the above analyses and no evidence for significant publication bias.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety outcomes</head><p>TAPT was associated with a numerically increased risk of major (IRR=1.24; 95% CI 0.79 to 1.92) (figure 4A), minor (IRR=1.37; 95% CI 0.88 to 2.14) ( <ref type="figure" target="#fig_5">figure 4B</ref>), or any bleeding (IRR=1.26; 95% CI 0.99 to 1.61) ( <ref type="figure" target="#fig_5">figure  4C</ref>) compared with DAPT, although these were not statistically significant. TAPT was also associated with a 59% increase in drug discontinuation due to adverse events (IRR=1.59; 95% CI 1.32 to 1.91) ( <ref type="figure" target="#fig_5">figure 4D</ref>) when compared with DAPT. The most commonly listed causes for drug discontinuation were headache, skin rash and palpitations/tachycardia. There was no-to-modest (for drug discontinuation outcomes) heterogeneity in all of the above analyses and no evidence for significant publication bias. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>In patients undergoing PCI, TAPT using cilostazol results in significant decrease in platelet reactivity and reduced risk of HTPR. TAPT resulted in significantly lower mean PRU, greater platelet inhibition and reduced risk of HTPR in the setting of DAPT with both standard-dose and high-dose clopidogrel. In addition, TAPT was associated with a significant reduction in CV events, including reduction in MACE, driven largely by significant reductions in TLR and TVR. Most importantly, there was a significant lower stent thrombosis with TAPT versus DAPT. Moreover, the reduction of restenosis with TAPT remained even when the analysis was restricted to trials using DES. In addition, there was numerically higher bleeding with TAPT versus DAPT, although this did not reach statistical significant. Patients with long or multivessel disease undergoing PCI ++± ACCEL-AMI <ref type="bibr" target="#b28">29</ref> Patients with ACS undergoing PCI +++ ACCEL-LOADING-ACS <ref type="bibr" target="#b29">30</ref> Patients with non-ST-elevation MI undergoing PCI ±±± ACCEL-RESISTANCE <ref type="bibr" target="#b32">33</ref> Patients with high on-treatment platelet reactivity undergoing PCI ++± Ahn et al <ref type="bibr" target="#b47">47</ref> Patient with ACS undergoing PCI ±±+ Chen et al <ref type="bibr" target="#b48">48</ref> Patients with ACS undergoing PCI ±++ CIDES <ref type="bibr" target="#b49">49</ref> Patients with diabetes undergoing PCI ±±± CILON-T <ref type="bibr" target="#b33">34</ref> Patients with angina undergoing PCI ++± CLEAR <ref type="bibr" target="#b50">50</ref> Patients with stable angina undergoing PCI ±±± CREST <ref type="bibr" target="#b51">51</ref> Patients with ACS/known stenosis undergoing PCI +++ DECLARE-DIABETES <ref type="bibr" target="#b52">52</ref> Patients with ACS and diabetes undergoing PCI +±± DECLARE-LONG <ref type="bibr" target="#b54">54</ref> Patients with ACS and stenosis of long (&gt;25 mm) lesions undergoing PCI +±± DECLARE-LONG II <ref type="bibr" target="#b55">55</ref> Patients with ACS/known stenosis of long (&gt;25 mm) lesions undergoing PCI +++ Gao et al <ref type="bibr" target="#b34">35</ref> Obese patients undergoing PCI ±±± Guan et al <ref type="bibr" target="#b35">36</ref> Patients with ACS and high on-treatment platelet reactivity undergoing PCI ±±± Han et al <ref type="bibr" target="#b56">56</ref> Patients with ACS undergoing PCI ++± Han et al <ref type="bibr" target="#b57">57</ref> Patients with ACS undergoing PCI ±±± HOST-ASSURE <ref type="bibr" target="#b37">37</ref> All-comer patients undergoing PCI ±±+ Hu et al <ref type="bibr" target="#b58">58</ref> Patients with ACS undergoing PCI ±±± Jin et al <ref type="bibr" target="#b39">39</ref> Patients undergoing PCI ±++ Kim et al <ref type="bibr" target="#b59">59</ref> Patients with ACS/known stenosis undergoing PCI ±±± Kim et al <ref type="bibr" target="#b41">41</ref> Patients with ST-elevation MI undergoing PCI ±±± Kum et al <ref type="bibr" target="#b42">42</ref> Patients with ACS/known stenosis undergoing PCI ±±± Lee et al <ref type="bibr" target="#b60">60</ref> Patients undergoing elective PCI +±± LONG-DES-II <ref type="bibr" target="#b61">61</ref> Patients with stenosis of long lesions undergoing PCI ++± Lu et al <ref type="bibr" target="#b70">70</ref> Patients undergoing PCI ±±+ Lu et al <ref type="bibr" target="#b64">64</ref> Patients with ADP-induced platelet inhibition rates &lt;30% undergoing PCI +±± Min et al <ref type="bibr" target="#b9">10</ref> Patients with ACS/known stenosis undergoing elective PCI ±+± OPTIMUS-2 <ref type="bibr" target="#b5">6</ref> Patients with diabetes undergone PCI +++ Shen et al <ref type="bibr" target="#b65">65</ref> Patients with ACS undergoing PCI ±±± Suh et al <ref type="bibr" target="#b66">66</ref> Patients with diabetes and chronic total occlusion undergoing PCI ±±± Wang et al <ref type="bibr" target="#b67">67</ref> Patients with small vessel stenosis undergoing PCI ±±± Wang et al <ref type="bibr" target="#b68">68</ref> Patients with non-ST-elevation MI undergoing PCI ±±± Zang et al <ref type="bibr" target="#b69">69</ref> Patients with ACS undergoing PCI ±±± However, there was a significant increase in the risk of drug discontinuation due to adverse effects when compared with DAPT.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Platelet reactivity and outcomes</head><p>Prior studies have shown a relationship between on-treatment platelet reactivity and adverse CV events in patients undergoing PCI. In an analysis of individual patient data from six studies with 3059 patients, for every 10 U increase in PRU there was a 4% increase in primary endpoint rate of death, MI or stent thrombosis (HR 1.04; 95% CI 1.03 to 1.06; p&lt;0.0001). <ref type="bibr" target="#b16">17</ref> A recent consensus statement recommended a cut-off of PRU &gt;235 U as the threshold for identifying patients with HTPR who may be at high risk for ischaemic or thrombotic events following PCI. <ref type="bibr" target="#b12">13</ref> Patients with HTPR have been shown to have an increased risk of death (110% increase), MI (104% increase) and stent thrombosis (211% increase). <ref type="bibr">17 18</ref> Although platelet reactivity is a surrogate marker, given the wide interindividual variability in clopidogrelinduced platelet inhibition, <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref> various strategies have been tested to improve platelet inhibition. These strategies have utilised higher loading and maintenance doses of clopidogrel, or next-generation P2Y12 inhibitors such as prasugrel and ticagrelor, which are more potent that clopidogrel and have a more uniform antiplatelet effect. Doubling of the clopidogrel dose (150 mg) has been shown to significantly reduce PRU in patients with HTPR. <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref> Similarly, data from the next-generation P2Y12 inhibitors such as prasugrel and ticagrelor have shown improved platelet reactivity indices when compared with clopidogrel. <ref type="bibr" target="#b21">22</ref> Although the newer agents prasugrel and ticagrelor reduce MACE in randomised trials, these agents increase bleeding in patients with PCI and cost significantly more than generic clopidogrel. <ref type="bibr">23 24</ref> Cilostazol, a phosphodiesterase III inhibitor, exhibits antiplatelet effects by increasing cAMP within platelets, and is available as a generic drug. Our results show a significant benefit of TAPT with cilostazol in improving platelet reactivity indices in patients undergoing PCI, with lower PRU, greater platelet inhibition and a significant reduction in the risk of HTPR regardless of comparison with either standard-dose or high-dose clopidogrel. In addition, these results were seen even in comparison with DAPT using high-dose clopidogrel. Given that generic clopidogrel is now available, many clinicians opt to prescribe high-dose clopidogrel to address HTPR in patients who cannot afford newer antiplatelet agents. The results of the present study show that TAPT with cilostazol is superior even to DAPT with high-dose clopidogrel. Despite these promising results, a number of limitations must be acknowledged. Although platelet reactivity is a risk factor/surrogate marker for adverse CV events, clinical studies have not yet demonstrated that a pharmacological treatment strategy based on platelet reactivity improves outcomes. <ref type="bibr">20 25</ref> In the ARCTIC trial of 2440 patients randomised to platelet-function monitoring and drug adjustment group versus conventional strategy of no monitoring and drug adjustment, there were no differences in composite of death, MI, stent thrombosis, stroke, or urgent revascularisation at 1 year between the two groups, calling into question the utility of adjusting therapies based on platelet function monitoring. <ref type="bibr" target="#b24">25</ref> However, because cilostazol inhibits both platelet activation and smooth muscle proliferation, it has the potential to target two dreaded complications of PCI-stent thrombosis and restenosis. TAPT may reduce MACE by two or more cellular mechanisms. <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> Our study shows  Therefore, a strategy of using TAPT with cilostazol has several advantages: (1) it improves the surrogate outcome of platelet reactivity relative to DAPT, including high-dose clopidogrel; (2) the antismooth muscle proliferative properties of cilostazol may make it an excellent agent to prevent restenosis resulting in reduced TVR even in patients treated with a DES; (3) the improvement in platelet reactivity indices translate into significant reduction in stent thrombosis and (4) the medication is available generically and is therefore less expensive than newer antiplatelet therapy. Thus, when used following PCI, TAPT with cilostazol has the potential to be a cost-effective therapy to improve clinical outcomes by reducing thrombotic events and restenosis. The results of this study <ref type="figure" target="#fig_3">Figure 3</ref> Continued therefore call for a randomised trial comparing a strategy of TAPT with DAPT using newer antiplatelet agents.</p><p>Our results differ from the studies of Jang et al <ref type="bibr" target="#b25">26</ref> and Sakurai et al <ref type="bibr" target="#b26">27</ref> in that these studies did not evaluate platelet reactivity outcomes and had far fewer trials than the current analysis. In our analysis, TAPT was associated with significant increase in drug discontinuation. The most commonly listed causes for drug discontinuation were headache, skin rash and palpitations/tachycardia. Sakurai et al 27 similarly found a significant increase in rash and gastrointestinal side effects with TAPT. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study limitations</head><p>As in other meta-analyses without individual patient data, we were unable to adjust for dosages of medication used or with compliance with assigned therapies. Given heterogeneity in the study protocols, clinically relevant differences could have been missed and are best assessed in a meta-analysis of individual patient data. Stroke would have been interesting to examine, as there is some evidence that cilostazol reduces stroke. <ref type="bibr" target="#b27">28</ref> All of the trials did not report all of the outcomes. The subgroup analyses might suffer from multiple testing. In addition, the results need to be confirmed in an ethnically diverse population, as most of the trials were done in Asian populations. However, the CREST and the OPTIMUS-2 trials, performed mainly in a non-Asian population, showed similar efficacy of cilostazol when compared with controls. The individual trials did not provide sufficient data to stratify analyses by early versus newer generation DES.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p>In patients undergoing PCI, TAPT with cilostazol is associated with significantly improved platelet reactivity indices, even when compared with DAPT with high- <ref type="figure" target="#fig_5">Figure 4</ref> Continued dose clopidogrel, and is associated with significant reduction in CV events, including reduction in BMS and DES restenosis and stent thrombosis. The dual properties of antiplatelet and antiproliferative action, the availability as a generic medication combined with the above data makes TAPT with aspirin, clopidogrel and cilostazol an attractive and strong competitor for newer antiplatelet regimens and should be evaluated in future trials.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc>Study selection.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 (</head><label>2</label><figDesc>A) Primary platelet reactivity outcome: difference in platelet reactivity units (PRU) after treatment between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary platelet reactivity outcome: difference in percent platelet inhibition after treatment between TAPT versus DAPT. (C) Secondary platelet reactivity outcome: risk of high on-treatment platelet reactivity (HTPR) after treatment between TAPT versus DAPT.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2</head><label>2</label><figDesc>Continuedsignificant reduction in both stent thrombosis and restenosis using TAPT with cilostazol, even in patients treated with DES. This is a potential advantage for this agent, as no antiplatelet agent, including prasugrel or ticagrelor, has been shown to have any antirestenosis property.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 (</head><label>3</label><figDesc>A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Secondary cardiovascular outcome: risk of all-cause mortality between TAPT versus DAPT. (C) Secondary cardiovascular outcome: risk of myocardial infarction between TAPT versus DAPT. (D) Secondary cardiovascular outcome: risk of target lesion revascularisation (TLR) between TAPT versus DAPT. (E) Secondary cardiovascular outcome: risk of target vessel revascularisation (TVR) between TAPT versus DAPT. (F) Secondary cardiovascular outcome: risk of stent thrombosis between TAPT versus DAPT.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3</head><label>3</label><figDesc>Continued</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 4 (</head><label>4</label><figDesc>A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (B) Safety outcome: risk of minor bleeding between TAPT versus DAPT. (C) Safety outcome: risk of any bleeding between TAPT versus DAPT. (D) Safety outcome: risk of drug discontinuation due to adverse effects between TAPT versus DAPT.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc>Baseline characteristics of included trials for platelet reactivity outcomes Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; HD, high-dose clopidogrel (150 mg); HOST-ASSURE, Harmonising Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety and Effectiveness of Drug-Eluting Stents and Antiplatelet Regimen; NR, not reported; PIANO-2 CKD, Platelet Reactivity in Patients with Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared with a High-Maintenance Dose of Clopidogrel; SD, Standard-dose clopidogrel (75 mg).</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>SD or HD</cell><cell>Mean age</cell><cell>Follow-up</cell></row><row><cell>Trial</cell><cell>Year N</cell><cell>Comparison</cell><cell>(DAPT group)</cell><cell>(years)</cell><cell>(days)</cell></row><row><cell>ACCEL-AMI 29</cell><cell>90</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>Both</cell><cell>62</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACCEL-LOADING-ACS 30</cell><cell>218</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>SD</cell><cell>63</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">ACCEL-POLYMORPHISM 31 134</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>HD</cell><cell>63</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACCEL-PPI 32</cell><cell>90</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>HD</cell><cell>NR</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACCEL-RESISTANCE 33</cell><cell>60</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>HD</cell><cell>63</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CILON-T 34</cell><cell>716</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>SD</cell><cell>64</cell><cell>180</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gao et al 35</cell><cell>428</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>SD</cell><cell>56</cell><cell>365</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Guan et al 36</cell><cell>840</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>SD</cell><cell>60</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HOST-ASSURE 37</cell><cell cols="2">1356 Aspirin/clopidogrel/cilostazol</cell><cell>Both</cell><cell>63</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Jeong et al 38</cell><cell>275</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>Both</cell><cell>NR</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Jin et al 39</cell><cell>60</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>HD</cell><cell>62</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Kim et al 40</cell><cell>126</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>HD</cell><cell>62</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Kim et al 41</cell><cell>60</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>SD</cell><cell>63</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Kum et al 42</cell><cell>66</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>SD</cell><cell>62</cell><cell>14</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lee et al 43</cell><cell>63</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>Both</cell><cell>NR</cell><cell>14</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>PIANO-2 CKD 44</cell><cell>74</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>Both</cell><cell>53</cell><cell>14</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Shim et al 45</cell><cell>379</cell><cell>Aspirin/clopidogrel/cilostazol</cell><cell>SD</cell><cell>61</cell><cell>14</cell></row><row><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row></table><note>ACCEL-AMI, adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in patients with AMI; ACCEL-LOADING-ACS, Multicentre Randomised Trial Evaluating Efficacy of Cilostazol on Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients; ACCEL-POLYMORPHISM, Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention; ACCEL-PPI, Pharmacodynamics Effects of Adding Cilostazol versus Double-dose Clopidogrel in Patients with Acute Myocardial Infarction During Proton Pump Inhibitor Co-administration; ACCEL-RESISTANCE, Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance; CILON-T,</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc>Inclusion criteria and study quality for platelet reactivity outcomes trials</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Platelet</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>reactivity</cell><cell>Quality of</cell></row><row><cell>Trial</cell><cell>Cohort</cell><cell>Definition of HTPR</cell><cell>assay</cell><cell>study*</cell></row><row><cell>ACCEL-AMI 29</cell><cell>Patients with ACS undergoing</cell><cell>5 and 20 μM ADP-induced</cell><cell>VerifyNow</cell><cell>+++</cell></row><row><cell></cell><cell>PCI</cell><cell>maximal platelet aggregation</cell><cell>P2Y12; LTA</cell><cell></cell></row><row><cell></cell><cell></cell><cell>&gt;50%</cell><cell></cell><cell></cell></row><row><cell>ACCEL-LOADING-ACS 30</cell><cell>Patients with non-ST-elevation MI</cell><cell>NR</cell><cell>VerifyNow</cell><cell>±±±</cell></row><row><cell></cell><cell>undergoing PCI</cell><cell></cell><cell>P2Y12</cell><cell></cell></row><row><cell cols="2">ACCEL-POLYMORPHISM 31 Patients with high post-treatment</cell><cell>5 μM ADP-induced maximal</cell><cell>VerifyNow</cell><cell>+++</cell></row><row><cell></cell><cell>platelet reactivity or diabetes</cell><cell>platelet aggregation &gt;50%</cell><cell>P2Y12; LTA</cell><cell></cell></row><row><cell></cell><cell>undergoing PCI</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACCEL-PPI 32</cell><cell>Patients with acute MI</cell><cell>20 μM ADP-induced</cell><cell>LTA</cell><cell>±±±</cell></row><row><cell></cell><cell>undergoing PCI</cell><cell>maximal platelet aggregation</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>&gt;59%</cell><cell></cell><cell></cell></row><row><cell>ACCEL-RESISTANCE 33</cell><cell>Patients with high on-treatment</cell><cell>5 μM ADP-induced maximal</cell><cell>VerifyNow</cell><cell>++±</cell></row><row><cell></cell><cell>platelet reactivity undergoing PCI</cell><cell>platelet aggregation &gt;50%</cell><cell>P2Y12; LTA</cell><cell></cell></row><row><cell>CILON-T 34</cell><cell>Patients with angina undergoing</cell><cell>NR</cell><cell>VerifyNow</cell><cell>++±</cell></row><row><cell></cell><cell>PCI</cell><cell></cell><cell>P2Y12</cell><cell></cell></row><row><cell>Gao et al 35</cell><cell>Obese patients undergoing PCI</cell><cell>Post-treatment platelet</cell><cell>LTA</cell><cell>±±±</cell></row><row><cell></cell><cell></cell><cell>aggregation absolute</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>difference 10% or less</cell><cell></cell><cell></cell></row><row><cell>Guan et al 36</cell><cell>Patients with ACS and high</cell><cell>20 μM ADP-induced</cell><cell>LTA</cell><cell>±±±</cell></row><row><cell></cell><cell>on-treatment platelet reactivity</cell><cell>maximal platelet aggregation</cell><cell></cell><cell></cell></row><row><cell></cell><cell>undergoing PCI</cell><cell>&gt;55%</cell><cell></cell><cell></cell></row><row><cell>HOST-ASSURE 37</cell><cell>All-comer patients undergoing</cell><cell>NR</cell><cell>VerifyNow</cell><cell>±±+</cell></row><row><cell></cell><cell>PCI</cell><cell></cell><cell>P2Y12</cell><cell></cell></row><row><cell>Jeong et al 38</cell><cell>Patients with ACS undergoing</cell><cell>NR</cell><cell>LTA</cell><cell>±±±</cell></row><row><cell></cell><cell>PCI</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Jin et al 39</cell><cell>Patients undergoing PCI</cell><cell>% platelet inhibition &lt;20</cell><cell>VerifyNow</cell><cell>±++</cell></row><row><cell></cell><cell></cell><cell></cell><cell>P2Y12; LTA</cell><cell></cell></row><row><cell>Kim et al 40</cell><cell>Patients with acute MI</cell><cell>20 μM ADP-induced</cell><cell>VerifyNow</cell><cell>++±</cell></row><row><cell></cell><cell>undergoing PCI</cell><cell>maximal platelet aggregation</cell><cell>P2Y12; LTA</cell><cell></cell></row><row><cell></cell><cell></cell><cell>&gt;59%</cell><cell></cell><cell></cell></row><row><cell>Kim et al 41</cell><cell>Patients with ST-elevation MI</cell><cell>% platelet inhibition &lt;20</cell><cell>VerifyNow</cell><cell>±±±</cell></row><row><cell></cell><cell>undergoing PCI</cell><cell></cell><cell>P2Y12; LTA</cell><cell></cell></row><row><cell>Kum et al 42</cell><cell>Patients undergoing PCI</cell><cell>NR</cell><cell>VerifyNow</cell><cell>±±±</cell></row><row><cell></cell><cell></cell><cell></cell><cell>P2Y12</cell><cell></cell></row><row><cell>Lee et al 43</cell><cell>Patients with high on-treatment</cell><cell>% platelet inhibition &lt;20</cell><cell>VerifyNow</cell><cell>+±±</cell></row><row><cell></cell><cell>platelet reactivity undergoing PCI</cell><cell></cell><cell>P2Y12</cell><cell></cell></row><row><cell>PIANO-2 CKD 44</cell><cell>Patients with renal disease on</cell><cell>5 μM ADP-induced maximal</cell><cell>VerifyNow</cell><cell>+++</cell></row><row><cell></cell><cell>haemodialysis undergoing PCI</cell><cell>platelet aggregation &gt;50%</cell><cell>P2Y12; LTA</cell><cell></cell></row><row><cell>Shim et al 45</cell><cell>Patients undergoing PCI with</cell><cell>% platelet inhibition &lt;20</cell><cell>VerifyNow</cell><cell>+±±</cell></row><row><cell></cell><cell>DES</cell><cell></cell><cell>P2Y12</cell><cell></cell></row></table><note>*Represents risk of bias based on: sequence generation of allocation; allocation concealment and blinding. '+' represents low bias risk, '−' high bias risk and '±' unclear bias risk. ACCEL-AMI, adjunctive Cilostazol versus High Maintenance Dose Clopidogrel in patients with AMI; ACCEL-LOADING-ACS, Multicentre Randomised Trial Evaluating Efficacy of Cilostazol on Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients; ACCEL-POLYMORPHISM, Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention; ACCEL-PPI, Pharmacodynamics Effects of Adding Cilostazol versus Double-dose Clopidogrel in Patients with Acute Myocardial Infarction During Proton Pump Inhibitor Co-administration; ACCEL-RESISTANCE, Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance; ACS, acute coronary syndrome; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; HD, high-dose clopidogrel (150 mg); HOST-ASSURE, Harmonising Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety and Effectiveness of Drug-Eluting Stents and Antiplatelet Regimen; LTA, light transmittance aggregometry; MI, myocardial infarction; NR, not reported; PIANO-2 CKD, Platelet Reactivity in Patients with Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared with a High-Maintenance Dose of Clopidogrel; SD, Standard-dose clopidogrel (75 mg).</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc>Baseline characteristics of included trials for cardiovascular outcomes</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Mean</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Follow-up</cell><cell>age</cell><cell>DM</cell><cell>DES</cell></row><row><cell>Trial</cell><cell cols="2">Year N</cell><cell>Comparison</cell><cell>(months)</cell><cell>(years)</cell><cell>(%) Stent type</cell><cell>(%)</cell></row><row><cell>ABCD 46</cell><cell>2014</cell><cell cols="2">630 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>65</cell><cell>31 BES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACCEL-AMI 29</cell><cell>2010</cell><cell></cell><cell>90 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>62</cell><cell>PES&gt;SES&gt;ZES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACCEL-</cell><cell>2012</cell><cell cols="2">218 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>63</cell><cell>23 DES, BMS</cell><cell>95</cell></row><row><cell>LOADING-</cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACS 30</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACCEL-</cell><cell>2009</cell><cell></cell><cell>60 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>63</cell><cell>23 DES</cell><cell>100</cell></row><row><cell>RESISTANCE 33</cell><cell></cell><cell></cell><cell>vs aspirin/high-dose</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ahn CM et al 47</cell><cell>2011</cell><cell cols="2">130 Aspirin/clopidogrel/cilostazol</cell><cell>24</cell><cell>64</cell><cell>22 SES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Chen YD et al 48 2006</cell><cell cols="2">120 Aspirin/clopidogrel/cilostazol</cell><cell>9</cell><cell>58</cell><cell>30 BMS</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CIDES 49</cell><cell>2008</cell><cell cols="2">280 Aspirin/clopidogrel/cilostazol</cell><cell>6</cell><cell>62</cell><cell>100 PES, SES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CILON-T 34</cell><cell>2011</cell><cell cols="2">960 Aspirin/clopidogrel/cilostazol</cell><cell>6</cell><cell>64</cell><cell>34 PES, ZES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CLEAR 50</cell><cell>2011</cell><cell cols="2">120 Aspirin/clopidogrel/cilostazol</cell><cell>6</cell><cell>66</cell><cell cols="2">42 SES&gt;ZES&gt;PES&gt;EES 100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CREST 51</cell><cell>2005</cell><cell cols="2">705 Aspirin/clopidogrel/cilostazol</cell><cell>6</cell><cell>60</cell><cell>26 BMS</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>DECLARE-</cell><cell>2008/</cell><cell cols="2">450 Aspirin/clopidogrel/cilostazol</cell><cell>24</cell><cell>61</cell><cell>100 PES, SES</cell><cell>100</cell></row><row><cell>DIABETES 52 53</cell><cell>2010</cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>DECLARE-</cell><cell>2007/</cell><cell cols="2">450 Aspirin/clopidogrel/cilostazol</cell><cell>24</cell><cell>61</cell><cell>33 PES, SES</cell><cell>100</cell></row><row><cell>LONG 53 54</cell><cell>2010</cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>DECLARE-</cell><cell>2011</cell><cell cols="2">499 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>62</cell><cell>35 ZES</cell><cell>100</cell></row><row><cell>LONG II 55</cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gao et al 35</cell><cell>2013</cell><cell cols="2">428 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>56</cell><cell>18 SES&gt;PES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Guan et al 36</cell><cell>2012</cell><cell cols="2">840 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>60</cell><cell>NR DES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Han et al 56</cell><cell cols="3">2009 1212 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>60</cell><cell>22 BMS, DES</cell><cell>52</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Han et al 57</cell><cell>2006</cell><cell cols="2">120 Aspirin/clopidogrel/cilostazol</cell><cell>3</cell><cell>61</cell><cell>23 BMS, DES</cell><cell>43</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>HOST-</cell><cell cols="3">2013 3755 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>63</cell><cell>32 ZES-R&gt;EES-PtCr</cell><cell>100</cell></row><row><cell>ASSURE 37</cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hu et al 58</cell><cell>2013</cell><cell cols="2">146 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>63</cell><cell>NR NR</cell><cell>NR</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Jin et al 39</cell><cell>2012</cell><cell></cell><cell>60 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>62</cell><cell>45 DES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Kim et al 59</cell><cell>2008</cell><cell cols="2">109 Aspirin/clopidogrel/cilostazol</cell><cell>6</cell><cell>68</cell><cell>29 PES&gt;SES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Kim et al 41</cell><cell>2007</cell><cell></cell><cell>60 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>63</cell><cell>29 SES&gt;PES&gt;others</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Kum et al 42</cell><cell>2009</cell><cell cols="2">603 Aspirin/clopidogrel/cilostazol</cell><cell>6</cell><cell>62</cell><cell>26 DES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lee et al 60</cell><cell>2007</cell><cell></cell><cell>20 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>56</cell><cell>25 NR</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>LONG-</cell><cell>2007</cell><cell cols="2">500 Aspirin/clopidogrel/cilostazol</cell><cell>9</cell><cell>61</cell><cell>33 PES, SES</cell><cell>100</cell></row><row><cell>DES-II 61 62</cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lu et al 63</cell><cell>2006</cell><cell cols="2">120 Aspirin/clopidogrel/cilostazol</cell><cell>6-9</cell><cell>71</cell><cell>NR BMS</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lu et al 64</cell><cell>2007</cell><cell cols="2">402 Aspirin/clopidogrel/cilostazol</cell><cell>6</cell><cell>61</cell><cell>44 BMS, DES</cell><cell>85</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Continued</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3 Continued</head><label>3</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Mean</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Follow-up</cell><cell>age</cell><cell>DM</cell><cell>DES</cell></row><row><cell>Trial</cell><cell cols="2">Year N</cell><cell>Comparison</cell><cell>(months)</cell><cell>(years)</cell><cell>(%) Stent type</cell><cell>(%)</cell></row><row><cell>Min et al 10</cell><cell>2007</cell><cell></cell><cell>59 Aspirin/clopidogrel or</cell><cell>6</cell><cell>62</cell><cell>26 BMS</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell>ticlopidine/cilostazol vs</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>aspirin/clopidogrel or</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>ticlopidine</cell><cell></cell><cell></cell><cell></cell></row><row><cell>OPTIMUS-2 6</cell><cell>2008</cell><cell></cell><cell>50 Aspirin/clopidogrel/cilostazol</cell><cell>1</cell><cell>64</cell><cell>100 NR</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Shen et al 65</cell><cell>2010</cell><cell cols="2">160 Aspirin/Clopidogrel/</cell><cell>12</cell><cell>69</cell><cell>100 DES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>Cilostazol vs Aspirin/</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Suh et al 66</cell><cell>2009</cell><cell cols="2">143 Aspirin/clopidogrel/cilostazol</cell><cell>25</cell><cell>62</cell><cell>100 PES&gt;SES</cell><cell>100</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Wang et al 67</cell><cell>2005</cell><cell cols="2">193 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>62</cell><cell>28 BMS</cell><cell>0</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Wang et al 68</cell><cell>2010</cell><cell cols="2">164 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>68</cell><cell>NR BMS, DES</cell><cell>NR</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Zang et al 69</cell><cell>2008</cell><cell cols="2">263 Aspirin/clopidogrel/cilostazol</cell><cell>12</cell><cell>59</cell><cell>100 BMS, DES</cell><cell>53</cell></row><row><cell></cell><cell></cell><cell></cell><cell>vs aspirin/clopidogrel</cell><cell></cell><cell></cell><cell></cell></row></table><note>ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent; BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES, Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent. Other trial expansions as in tables 1 and 2.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4</head><label>4</label><figDesc>Inclusion criteria and study quality of included cardiovascular outcomes trials</figDesc><table><row><cell>Trial</cell><cell>Cohort</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head></head><label></label><figDesc>Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES, Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent. Other trial expansions as in tables 1 and 2.</figDesc><table /><note>*Represents risk of bias based on: sequence generation of allocation; allocation concealment and blinding. '+' represents low bias risk, '−' high bias risk and '±' unclear bias risk. ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent; BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T,</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Bangalore S, Singh A, Toklu B, et al. Open Heart 2014;1:e000068. doi:10.1136/openhrt-2014-000068</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Coronary artery disease</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Contributors SB was involved in study concept and design, analysis and interpretation of the data, statistical analysis, and study supervision and also takes responsibility for the integrity of the data and the accuracy of the data analysis. SB and AS were involved in acquisition of the data and drafting of the manuscript. SB, AS, JJD, KC, FF and DLB were involved in critical revision of the manuscript for important intellectual content.</p><p>Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Gurbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">P</forename><surname>Bliden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Hiatt</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.cir.0000072771.11429.83</idno>
		<idno type="PMID">12796140</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.0000072771.11429.83" />
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<title level="j" type="abbrev">Circulation</title>
		<idno type="ISSN">0009-7322</idno>
		<idno type="ISSNe">1524-4539</idno>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2908" to="2913" />
			<date type="published" when="2003-06-17" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Angiolillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Fernandez-Ortiz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Bernardo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1505" to="1521" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Variability in Platelet Responsiveness to Clopidogrel Among 544 Individuals</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">L</forename><surname>Serebruany</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">R</forename><surname>Steinhubl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Berger</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.accreview.2005.04.029</idno>
	</analytic>
	<monogr>
		<title level="j">ACC Current Journal Review</title>
		<title level="j" type="abbrev">ACC Current Journal Review</title>
		<idno type="ISSN">1062-1458</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">31</biblScope>
			<date type="published" when="2005-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Effective platelet inhibition by aspirin and clopidogrel: where are we now?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Tousoulis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Briasoulis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Dhamrait</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Antoniades</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Stefanadis</surname></persName>
		</author>
		<idno type="DOI">10.1136/hrt.2008.152736</idno>
		<idno type="PMID">19401288</idno>
		<idno type="ark">ark:/67375/NVC-12G9SV8J-H</idno>
		<idno type="istexId">C1F3226B14A40FCAA41734123A6D6606DCAFA99B</idno>
	</analytic>
	<monogr>
		<title level="j">Heart</title>
		<title level="j" type="abbrev">Heart</title>
		<idno type="ISSN">1355-6037</idno>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="850" to="858" />
			<date type="published" when="2009-04-28" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dániel</forename><surname>Aradi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">András</forename><surname>Komócsi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">András</forename><surname>Vorobcsuk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Orsolya</forename><surname>Rideg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Margit</forename><surname>Tőkés-Füzesi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tamás</forename><surname>Magyarlaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Iván</forename><forename type="middle">Gábor</forename><surname>Horváth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Victor</forename><forename type="middle">L</forename><surname>Serebruany</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2010.06.004</idno>
		<idno type="PMID">20826265</idno>
	</analytic>
	<monogr>
		<title level="j">American Heart Journal</title>
		<title level="j" type="abbrev">American Heart Journal</title>
		<idno type="ISSN">0002-8703</idno>
		<imprint>
			<biblScope unit="volume">160</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="543" to="551" />
			<date type="published" when="2010-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Angiolillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Capranzano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Aslam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Desai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename><surname>Charlton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">C</forename><surname>Box</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">B</forename><surname>Shoemaker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Zenni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Guzman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">A</forename><surname>Bass</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehn287</idno>
		<idno type="PMID">18567918</idno>
		<idno type="ark">ark:/67375/HXZ-SLZRT4SQ-G</idno>
		<idno type="istexId">4AE294CD5BCAEB7D0133D20E4AC028A04F4F5582</idno>
		<ptr type="open-access" target="https://academic.oup.com/eurheartj/article-pdf/29/18/2202/1228645/ehn287.pdf" />
	</analytic>
	<monogr>
		<title level="j">European Heart Journal</title>
		<title level="j" type="abbrev">European Heart Journal</title>
		<idno type="ISSN">0195-668X</idno>
		<idno type="ISSNe">1522-9645</idno>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="2202" to="2211" />
			<date type="published" when="2008-03-13" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Cilostazol (Pletal®): A Dual Inhibitor of Cyclic Nucleotide Phosphodiesterase Type 3 and Adenosine Uptake</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yongge</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yasmin</forename><surname>Shakur</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masuhiro</forename><surname>Yoshitake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun-Ichi</forename><surname>Kambayashi</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1527-3466.2001.tb00076.x</idno>
	</analytic>
	<monogr>
		<title level="j">Cardiovascular Drug Reviews</title>
		<idno type="ISSN">0897-5957</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="369" to="386" />
			<date type="published" when="2006-06-07" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kazuya</forename><surname>Fujinaga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Koji</forename><surname>Onoda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kiyohito</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyoko</forename><surname>Imanaka-Yoshida</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Motoshi</forename><surname>Takao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takatsugu</forename><surname>Shimono</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideto</forename><surname>Shimpo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshimichi</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Isao</forename><surname>Yada</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jtcvs.2003.11.015</idno>
		<idno type="PMID">15354092</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Thoracic and Cardiovascular Surgery</title>
		<title level="j" type="abbrev">The Journal of Thoracic and Cardiovascular Surgery</title>
		<idno type="ISSN">0022-5223</idno>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="357" to="363" />
			<date type="published" when="2004-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chien-Sung</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng-Yen</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yung-Hsiang</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tung-Lin</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hsiao-Jung</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guo-Shine</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chih-Yuan</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi-Tin</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shing-Jong</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chi-Yuan</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1002/jcb.21388</idno>
		<idno type="PMID">17516547</idno>
		<idno type="ark">ark:/67375/WNG-7R8Z0T4Q-7</idno>
		<idno type="istexId">58EA442DD344BCC9F6CF3843D8DEE656CE412882</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Cellular Biochemistry</title>
		<title level="j" type="abbrev">J. Cell. Biochem.</title>
		<idno type="ISSN">0730-2312</idno>
		<idno type="ISSNe">1097-4644</idno>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="54" to="66" />
			<date type="published" when="2007" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Effect of Cilostazol on In-Stent Neointimal Hyperplasia After Coronary Artery Stenting</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pil-Ki</forename><surname>Min</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Hun</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Guk</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donghoon</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yangsoo</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won-Heum</forename><surname>Shim</surname></persName>
		</author>
		<idno type="DOI">10.1253/circj.71.1685</idno>
		<idno type="PMID">17965485</idno>
		<ptr type="open-access" target="https://www.jstage.jst.go.jp/article/circj/71/11/71_11_1685/_pdf" />
	</analytic>
	<monogr>
		<title level="j">Circulation Journal</title>
		<title level="j" type="abbrev">Circ J</title>
		<idno type="ISSN">1346-9843</idno>
		<idno type="ISSNe">1347-4820</idno>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1685" to="1690" />
			<date type="published" when="2007" />
			<publisher>Japanese Circulation Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seong-Wook</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung-Cheol</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hak</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Duk-Woo</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won-Jang</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong-Young</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheol</forename><forename type="middle">Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myeong-Ki</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Joong</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Jung</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2009.11.014</idno>
		<idno type="PMID">20152228</idno>
	</analytic>
	<monogr>
		<title level="j">American Heart Journal</title>
		<title level="j" type="abbrev">American Heart Journal</title>
		<idno type="ISSN">0002-8703</idno>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="284" to="291.e1" />
			<date type="published" when="2010-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions version. 500 edn</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Green</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008" />
			<publisher>The Cochrane Collaboration</publisher>
			<pubPlace>Oxford</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laurent</forename><surname>Bonello</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Udaya</forename><forename type="middle">S</forename><surname>Tantry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rossella</forename><surname>Marcucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruediger</forename><surname>Blindt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dominick</forename><forename type="middle">J</forename><surname>Angiolillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deepak</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marco</forename><surname>Cattaneo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean</forename><forename type="middle">Philippe</forename><surname>Collet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Cuisset</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Gachet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gilles</forename><surname>Montalescot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lisa</forename><forename type="middle">K</forename><surname>Jennings</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dean</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dirk</forename><surname>Sibbing</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dietmar</forename><surname>Trenk</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jochem</forename><forename type="middle">W</forename><surname>Van Werkum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Franck</forename><surname>Paganelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ron</forename><surname>Waksman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">A</forename><surname>Gurbel</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2010.04.047</idno>
		<idno type="PMID">20828644</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American College of Cardiology</title>
		<title level="j" type="abbrev">Journal of the American College of Cardiology</title>
		<idno type="ISSN">0735-1097</idno>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="919" to="933" />
			<date type="published" when="2010-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deborah</forename><forename type="middle">J</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Susan</forename><surname>Eastwood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ingram</forename><surname>Olkin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Drummond</forename><surname>Rennie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donna</forename><forename type="middle">F</forename><surname>Stroup</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1365-2168.2000.01610.x</idno>
		<idno type="PMID">11091231</idno>
		<idno type="ark">ark:/67375/WNG-W132MD5F-4</idno>
		<idno type="istexId">40ED8AABD0509D579FD8667225B95219353E7448</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/fa51/d2901ac8b58dcf0d49485ea80d9ccde1a25f.pdf" />
	</analytic>
	<monogr>
		<title level="j">British Journal of Surgery</title>
		<title level="j" type="abbrev">Br J Surg</title>
		<idno type="ISSN">0007-1323</idno>
		<idno type="ISSNe">1365-2168</idno>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1448" to="1454" />
			<date type="published" when="2000-11" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Green</surname></persName>
		</author>
		<ptr target="http://www.cochrane-handbook.org" />
		<imprint>
			<date type="published" when="2008-12" />
			<biblScope unit="page">12</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Measuring inconsistency in meta-analyses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">G</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Deeks</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.327.7414.557</idno>
		<idno type="PMID">12958120</idno>
		<idno type="PMCID">PMC192859</idno>
		<idno type="ark">ark:/67375/NVC-QJDCZCKZ-4</idno>
		<idno type="istexId">643263D3B945EA135ECBEE4BD099C0C6AB6BD09F</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc192859?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<title level="j" type="abbrev">BMJ</title>
		<idno type="ISSN">0959-8138</idno>
		<idno type="ISSNe">1468-5833</idno>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="issue">7414</biblScope>
			<biblScope unit="page" from="557" to="560" />
			<date type="published" when="2003-09-06" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">IMPACT OF CLOPIDOGREL ON-TREATMENT PLATELET REACTIVITY ON STENT THROMBOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM A COLLABORATIVE META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Somjot</forename><surname>Brar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jurrien</forename><surname>Ten Berg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rossella</forename><surname>Marcucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marco</forename><surname>Valgimigli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyo-Soo</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giuseppe</forename><surname>Patti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicoline</forename><surname>Breet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Germano</forename><surname>Disciascio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Cuisset</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><surname>Dangas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kaiser</forename><surname>Permanente</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0735-1097(11)61632-x</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American College of Cardiology</title>
		<title level="j" type="abbrev">Journal of the American College of Cardiology</title>
		<idno type="ISSN">0735-1097</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page">E1632</biblScope>
			<date type="published" when="2011-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Acceptance of High Platelet Reactivity as a Risk Factor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">A</forename><surname>Gurbel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Udaya</forename><forename type="middle">S</forename><surname>Tantry</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcin.2010.08.011</idno>
		<idno type="PMID">20965457</idno>
	</analytic>
	<monogr>
		<title level="j">JACC: Cardiovascular Interventions</title>
		<title level="j" type="abbrev">JACC: Cardiovascular Interventions</title>
		<idno type="ISSN">1936-8798</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1008" to="1010" />
			<date type="published" when="2010-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colin</forename><forename type="middle">M</forename><surname>Barker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sarah</forename><forename type="middle">S</forename><surname>Murray</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">S</forename><surname>Teirstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">E</forename><surname>Kandzari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><forename type="middle">J</forename><surname>Topol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcin.2010.07.012</idno>
		<idno type="PMID">20965456</idno>
	</analytic>
	<monogr>
		<title level="j">JACC: Cardiovascular Interventions</title>
		<title level="j" type="abbrev">JACC: Cardiovascular Interventions</title>
		<idno type="ISSN">1936-8798</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1001" to="1007" />
			<date type="published" when="2010-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthew</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">S</forename><surname>Teirstein</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2011.290</idno>
		<idno type="PMID">21406646</idno>
		<ptr type="open-access" target="https://jamanetwork.com/journals/jama/articlepdf/646144/joc15014_1097_1105.pdf" />
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<title level="j" type="abbrev">JAMA</title>
		<idno type="ISSN">0098-7484</idno>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page">1097</biblScope>
			<date type="published" when="2011-03-16" />
			<publisher>American Medical Association (AMA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Angiolillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">S</forename><surname>Teirstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Lillie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">V</forename><surname>Manoukian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-F</forename><surname>Tanguay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">P</forename><surname>Cannon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">J</forename><surname>Topol</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.111.029165</idno>
		<idno type="PMID">21875913</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.111.029165" />
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<title level="j" type="abbrev">Circulation</title>
		<idno type="ISSN">0009-7322</idno>
		<idno type="ISSNe">1524-4539</idno>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1132" to="1137" />
			<date type="published" when="2011-08-29" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alan</forename><forename type="middle">D</forename><surname>Michelson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">L</forename><surname>Frelinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eugene</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><forename type="middle">E</forename><surname>Downey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dominick</forename><forename type="middle">J</forename><surname>Angiolillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nicholas</forename><forename type="middle">P</forename><surname>Xenopoulos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><forename type="middle">A</forename><surname>Jakubowski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Youfu</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sabina</forename><forename type="middle">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carolyn</forename><forename type="middle">H</forename><surname>Mccabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elliott</forename><forename type="middle">M</forename><surname>Antman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">D</forename><surname>Wiviott</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehp159</idno>
		<idno type="PMID">19435740</idno>
		<idno type="ark">ark:/67375/HXZ-WGNQNXP0-4</idno>
		<idno type="istexId">C92A768B9F57FDF8670D7E385069609241881D03</idno>
		<ptr type="open-access" target="https://academic.oup.com/eurheartj/article-pdf/30/14/1753/17889741/ehp159.pdf" />
	</analytic>
	<monogr>
		<title level="j">European Heart Journal</title>
		<idno type="ISSN">0195-668X</idno>
		<idno type="ISSNe">1522-9645</idno>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1753" to="1763" />
			<date type="published" when="2009-05-12" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">D</forename><surname>Wiviott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eugene</forename><surname>Braunwald</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carolyn</forename><forename type="middle">H</forename><surname>Mccabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gilles</forename><surname>Montalescot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Witold</forename><surname>Ruzyllo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shmuel</forename><surname>Gottlieb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Franz-Joseph</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diego</forename><surname>Ardissino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stefano</forename><surname>De Servi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sabina</forename><forename type="middle">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><surname>Riesmeyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Govinda</forename><surname>Weerakkody</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Michael</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elliott</forename><forename type="middle">M</forename><surname>Antman</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa0706482</idno>
		<idno type="PMID">17982182</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/2b93/e84c2b14a09d24fd28eec6567664f3d6ff6b.pdf" />
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="2001" to="2015" />
			<date type="published" when="2007-11-15" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lars</forename><surname>Wallentin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">C</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrzej</forename><surname>Budaj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Cannon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Håkan</forename><surname>Emanuelsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claes</forename><surname>Held</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jay</forename><surname>Horrow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steen</forename><surname>Husted</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stefan</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hugo</forename><surname>Katus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kenneth</forename><forename type="middle">W</forename><surname>Mahaffey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benjamin</forename><forename type="middle">M</forename><surname>Scirica</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Allan</forename><surname>Skene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philippe</forename><forename type="middle">Gabriel</forename><surname>Steg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">F</forename><surname>Storey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Harrington</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa0904327</idno>
		<idno type="PMID">19717846</idno>
		<ptr type="open-access" target="https://dea.lib.unideb.hu/dea/bitstream/2437/95141/1/ris_file_up_15_Wallentin-2009-Ticagrelor%20versus%20cl.pdf" />
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1045" to="1057" />
			<date type="published" when="2009-09-10" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Philippe</forename><surname>Collet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Cuisset</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Grégoire</forename><surname>Rangé</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guillaume</forename><surname>Cayla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simon</forename><surname>Elhadad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christophe</forename><surname>Pouillot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pascal</forename><surname>Motreff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Didier</forename><surname>Carrié</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ziad</forename><surname>Boueri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Loic</forename><surname>Belle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><surname>Van Belle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hélène</forename><surname>Rousseau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pierre</forename><surname>Aubry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jacques</forename><surname>Monségu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pierre</forename><surname>Sabouret</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">A</forename><surname>O'connor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jérémie</forename><surname>Abtan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mathieu</forename><surname>Kerneis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christophe</forename><surname>Saint-Etienne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Olivier</forename><surname>Barthélémy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Farzin</forename><surname>Beygui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Johanne</forename><surname>Silvain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><surname>Vicaut</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gilles</forename><surname>Montalescot</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa1209979</idno>
		<idno type="PMID">23121439</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/edb6/f2d2ca101eb61dd2cb5c29b81794805ed531.pdf" />
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2100" to="2109" />
			<date type="published" when="2012-11-29" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A Meta-Analysis of Randomized Controlled Trials Appraising the Efficacy and Safety of Cilostazol after Coronary Artery Stent Implantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Sik</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Han-Young</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeong-Sook</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae-Hyun</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dae-Kyeong</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dong-Soo</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dong-Kie</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sang-Hoon</forename><surname>Seol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Doo-Il</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyoung-Im</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bo-Hyun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yong</forename><forename type="middle">Hyun</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyung-Gon</forename><surname>Je</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hoon</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won-Jang</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong-Young</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Whan</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1159/000339238</idno>
		<idno type="PMID">22832424</idno>
	</analytic>
	<monogr>
		<title level="j">Cardiology</title>
		<title level="j" type="abbrev">Cardiology</title>
		<idno type="ISSN">0008-6312</idno>
		<idno type="ISSNe">1421-9751</idno>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="133" to="143" />
			<date type="published" when="2012" />
			<publisher>S. Karger AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: A meta-analysis of randomized controlled trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryota</forename><surname>Sakurai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bon-Kwon</forename><surname>Koo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideaki</forename><surname>Kaneda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Heidi</forename><forename type="middle">N</forename><surname>Bonneau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryozo</forename><surname>Nagai</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijcard.2012.06.010</idno>
		<idno type="PMID">22727963</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Cardiology</title>
		<title level="j" type="abbrev">International Journal of Cardiology</title>
		<idno type="ISSN">0167-5273</idno>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="2250" to="2258" />
			<date type="published" when="2013-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Secondary prevention of stroke: can we do better than aspirin?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dharam</forename><forename type="middle">J</forename><surname>Kumbhani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Deepak</forename><forename type="middle">L</forename><surname>Bhatt</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1474-4422(10)70217-9</idno>
		<idno type="PMID">20833590</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet Neurology</title>
		<title level="j" type="abbrev">The Lancet Neurology</title>
		<idno type="ISSN">1474-4422</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="942" to="943" />
			<date type="published" when="2010-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Adding Cilostazol to Dual Antiplatelet Therapy Achieves Greater Platelet Inhibition than High Maintenance Dose Clopidogrel in Patients With Acute Myocardial Infarction: Results of the Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With AMI (ACCEL-AMI) Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-H</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-Y</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I-S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-J</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-W</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1161/circinterventions.109.880179</idno>
		<idno type="PMID">20118150</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/CIRCINTERVENTIONS.109.880179" />
	</analytic>
	<monogr>
		<title level="j">Circulation: Cardiovascular Interventions</title>
		<title level="j" type="abbrev">Circulation: Cardiovascular Interventions</title>
		<idno type="ISSN">1941-7640</idno>
		<idno type="ISSNe">1941-7632</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="17" to="26" />
			<date type="published" when="2010-01-26" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">AS-001 Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Inhibition of Platelet Aggregation, Inflammation and Myonecrosis in ACS Patients Undergoing PCI: the Results of ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol LOADING in Patients with Acute Coronary Syndrome) Trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hoon</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyounghoon</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sang-Yong</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Hyeong</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jon</forename><surname>Suh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keun</forename><forename type="middle">Ho</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2012.02.002</idno>
		<idno>ACS patients. TCT-AP 2012</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Cardiology</title>
		<title level="j" type="abbrev">The American Journal of Cardiology</title>
		<idno type="ISSN">0002-9149</idno>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="S1" to="S2" />
			<date type="published" when="2012-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Cytochrome 2C19 Polymorphism and Response to Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-J</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-H</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I-S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K-S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-K</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-S</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E-H</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-Y</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1161/circinterventions.110.949859</idno>
		<idno type="PMID">20823393</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/CIRCINTERVENTIONS.110.949859" />
	</analytic>
	<monogr>
		<title level="j">Circulation: Cardiovascular Interventions</title>
		<title level="j" type="abbrev">Circulation: Cardiovascular Interventions</title>
		<idno type="ISSN">1941-7640</idno>
		<idno type="ISSNe">1941-7632</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="450" to="459" />
			<date type="published" when="2010-09-07" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">PHARMACODYNAMIC EFFECTS OF ADDING CILOSTAZOL VERSUS DOUBLE-DOSE CLOPIDOGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION DURING PROTON PUMP INHIBITOR CO-ADMINISTRATION (ACCEL-PPI)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hoon</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seok</forename><forename type="middle">Jae</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yongwhi</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bliden</forename><forename type="middle">P</forename><surname>Kevin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hwang</forename><surname>Jin-Yong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Choong</forename><forename type="middle">Hwan</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Udaya</forename><surname>Tantry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><surname>Gurbel</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0735-1097(12)60522-1</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American College of Cardiology</title>
		<title level="j" type="abbrev">Journal of the American College of Cardiology</title>
		<idno type="ISSN">0735-1097</idno>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page">E521</biblScope>
			<date type="published" when="2012-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-H</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">R</forename><surname>Choi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1101" to="1110" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-W</forename><surname>Suh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="280" to="289" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Efficacy and Safety of Triple Antiplatelet Therapy in Obese Patients Undergoing Stent Implantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wen</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qinghua</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hailong</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yonghe</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhiming</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.1177/0003319712474113</idno>
		<idno type="PMID">23359782</idno>
	</analytic>
	<monogr>
		<title level="j">Angiology</title>
		<title level="j" type="abbrev">Angiology</title>
		<idno type="ISSN">0003-3197</idno>
		<idno type="ISSNe">1940-1574</idno>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="554" to="558" />
			<date type="published" when="2013-01-27" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Y</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">L</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<title level="m">Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Zhonghua Xin Xue Guan Bing Za Zhi</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="25" to="34" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing optimal strategy for treatment of coronary artery stenosis-safety &amp; effectiveness of drug-eluting stents &amp; anti-platelet regimen)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="932" to="974" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">REAPPRAISAL OF PHARMACODYNAMIC EFFECT OF ADJUNCTIVE CILOSTAZOL AND HIGH-DOSE CLOPIDOGREL IN EAST ASIAN ACS PATIENTS</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hoon</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yongwhi</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><forename type="middle">Sin</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeong</forename><forename type="middle">Rang</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Choong</forename><forename type="middle">Hwan</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin-Yong</forename><surname>Hwang</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0735-1097(14)60232-1</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American College of Cardiology</title>
		<title level="j" type="abbrev">Journal of the American College of Cardiology</title>
		<idno type="ISSN">0735-1097</idno>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">A232</biblScope>
			<date type="published" when="2014-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Loading Effect of 200 mg Cilostazol on Platelet Inhibition in Patients Undergoing Percutaneous Coronary Intervention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">En</forename><forename type="middle">Ze</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Long</forename><forename type="middle">Hao</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xue</forename><forename type="middle">Qi</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1536/ihj.53.1</idno>
		<idno type="PMID">22398668</idno>
		<ptr type="open-access" target="https://www.jstage.jst.go.jp/article/ihj/53/1/53_1_1/_pdf" />
	</analytic>
	<monogr>
		<title level="j">International Heart Journal</title>
		<title level="j" type="abbrev">Int. Heart J.</title>
		<idno type="ISSN">1349-2365</idno>
		<idno type="ISSNe">1349-3299</idno>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2012" />
			<publisher>International Heart Journal (Japanese Heart Journal)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">In-Suk</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hoon</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yongwhi</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ki-Soo</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seong-Eun</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeong-Rang</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seok-Jae</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eun-Ha</forename><surname>Koh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Choong</forename><forename type="middle">Hwan</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin-Yong</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sunjoo</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jcin.2010.12.010</idno>
		<idno type="PMID">21511217</idno>
	</analytic>
	<monogr>
		<title level="j">JACC: Cardiovascular Interventions</title>
		<title level="j" type="abbrev">JACC: Cardiovascular Interventions</title>
		<idno type="ISSN">1936-8798</idno>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="381" to="391" />
			<date type="published" when="2011-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Cilostazol Could Ameliorate Platelet Responsiveness to Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jang-Young</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyounghoon</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myungsang</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Minsoo</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyunmin</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Byung-Su</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Junghan</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyung-Hoon</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Hwan</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1253/circj.722103</idno>
		<ptr type="open-access" target="https://www.jstage.jst.go.jp/article/circj/72/12/72_722103/_pdf" />
	</analytic>
	<monogr>
		<title level="j">Circulation Journal</title>
		<title level="j" type="abbrev">Circ J</title>
		<idno type="ISSN">1346-9843</idno>
		<idno type="ISSNe">1347-4820</idno>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page">2103</biblScope>
			<date type="published" when="2008" />
			<publisher>Japanese Circulation Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Clinical Effects of Additional Cilostazol Administration After Drug-Eluting Stent Insertion</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dong</forename><forename type="middle">Sung</forename><surname>Kum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Moo</forename><forename type="middle">Hyun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeung</forename><forename type="middle">Hoan</forename><surname>Paik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Long</forename><forename type="middle">Hao</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyung</forename><forename type="middle">Ho</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae</forename><forename type="middle">Ho</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kwang</forename><forename type="middle">Soo</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young</forename><forename type="middle">Dae</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mei</forename><forename type="middle">Lian</forename><surname>Quan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin</forename><forename type="middle">Yeong</forename><surname>Han</surname></persName>
		</author>
		<idno type="DOI">10.4070/kcj.2009.39.1.21</idno>
		<ptr type="open-access" target="http://synapse.koreamed.org/Synapse/Data/PDFData/0054KCJ/kcj-39-21.pdf" />
	</analytic>
	<monogr>
		<title level="j">Korean Circulation Journal</title>
		<title level="j" type="abbrev">Korean Circ J</title>
		<idno type="ISSN">1738-5520</idno>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">21</biblScope>
			<date type="published" when="2009" />
			<publisher>The Korean Society of Cardiology (KAMJE)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B-S</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">K</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-S</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-H</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1538-7836.2010.04019.x</idno>
		<idno type="PMID">20723027</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Thrombosis and Haemostasis</title>
		<idno type="ISSN">1538-7933</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2577" to="2579" />
			<date type="published" when="2010-11" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong</forename><forename type="middle">Shin</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weon</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sul</forename><forename type="middle">Ra</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyung</forename><forename type="middle">Hwan</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Woo</forename><forename type="middle">Shik</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae</forename><forename type="middle">Hwan</forename><surname>Lew</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae</forename><forename type="middle">Won</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chun</forename><forename type="middle">Kyu</forename><surname>Lim</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2011.09.003</idno>
		<idno type="PMID">22137075</idno>
	</analytic>
	<monogr>
		<title level="j">American Heart Journal</title>
		<title level="j" type="abbrev">American Heart Journal</title>
		<idno type="ISSN">0002-8703</idno>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1018" to="1025" />
			<date type="published" when="2011-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chi</forename><forename type="middle">Young</forename><surname>Shim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Se-Jung</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sungha</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jung-Sun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong</forename><forename type="middle">Rak</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Guk</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Donghoon</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong-Won</forename><surname>Ha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yangsoo</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Namsik</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won-Heum</forename><surname>Shim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Yun</forename><surname>Cho</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijcard.2008.02.016</idno>
		<idno type="PMID">18579227</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Cardiology</title>
		<title level="j" type="abbrev">International Journal of Cardiology</title>
		<idno type="ISSN">0167-5273</idno>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="351" to="355" />
			<date type="published" when="2009-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young</forename><forename type="middle">Jin</forename><surname>Youn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jun-Won</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung</forename><forename type="middle">Gyun</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Hwan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyunmin</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheol</forename><forename type="middle">Woong</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young</forename><forename type="middle">Joon</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyuck</forename><forename type="middle">Moon</forename><surname>Kwon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myeong-Ki</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yangsoo</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Junghan</forename><surname>Yoon</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2013.08.028</idno>
		<idno type="PMID">24439986</idno>
	</analytic>
	<monogr>
		<title level="j">American Heart Journal</title>
		<title level="j" type="abbrev">American Heart Journal</title>
		<idno type="ISSN">0002-8703</idno>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="241" to="248.e1" />
			<date type="published" when="2014-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chul</forename><forename type="middle">Min</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Soon</forename><forename type="middle">Jun</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae</forename><forename type="middle">Hyung</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae</forename><forename type="middle">Sang</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Do-Sun</forename><surname>Lim</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00380-010-0093-1</idno>
		<idno type="PMID">21153029</idno>
		<idno type="ark">ark:/67375/VQC-T4N40WJS-5</idno>
		<idno type="istexId">06FE46643506DD341A251F04BD91127B6E3583CA</idno>
	</analytic>
	<monogr>
		<title level="j">Heart and Vessels</title>
		<title level="j" type="abbrev">Heart Vessels</title>
		<idno type="ISSN">0910-8327</idno>
		<idno type="ISSNe">1615-2573</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="502" to="510" />
			<date type="published" when="2010-12-09" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-D</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Jin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin Med J</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="360" to="366" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Randomized Comparison of Cilostazol vs Clopidogrel After Drug-Eluting Stenting in Diabetic Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Youngkeun</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myung</forename><forename type="middle">Ho</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong</forename><forename type="middle">Weon</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kye</forename><forename type="middle">Hun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae</forename><forename type="middle">Hoon</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Woong</forename><forename type="middle">Chul</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang-Gyu</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong</forename><forename type="middle">Hyun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">In-Ho</forename><surname>Chae</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang</forename><forename type="middle">Wook</forename><surname>Nam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Ho</forename><surname>Hur</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jang-Ho</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ki</forename><forename type="middle">Young</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seok</forename><forename type="middle">Kyu</forename><surname>Oh</surname></persName>
		</author>
		<idno type="DOI">10.1253/circj.72.35</idno>
		<idno type="PMID">18159096</idno>
		<ptr type="open-access" target="https://www.jstage.jst.go.jp/article/circj/72/1/72_1_35/_pdf" />
	</analytic>
	<monogr>
		<title level="j">Circulation Journal</title>
		<title level="j" type="abbrev">Circ J</title>
		<idno type="ISSN">1346-9843</idno>
		<idno type="ISSNe">1347-4820</idno>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="35" to="39" />
			<date type="published" when="2008" />
			<publisher>Japanese Circulation Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">A Randomized Study Assessing the Effects of Pretreatment with Cilostazol on Periprocedural Myonecrosis after Percutaneous Coronary Intervention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Byeong-Keuk</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung</forename><forename type="middle">Jin</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Se-Jung</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dong</forename><forename type="middle">Woon</forename><surname>Jeon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Guk</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joo</forename><forename type="middle">Young</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.3349/ymj.2011.52.5.717</idno>
		<idno type="PMID">21786434</idno>
		<idno type="PMCID">PMC3159932</idno>
		<ptr type="open-access" target="http://synapse.koreamed.org/Synapse/Data/PDFData/0069YMJ/ymj-52-717.pdf" />
	</analytic>
	<monogr>
		<title level="j">Yonsei Medical Journal</title>
		<title level="j" type="abbrev">Yonsei Med J</title>
		<idno type="ISSN">0513-5796</idno>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">717</biblScope>
			<date type="published" when="2011" />
			<publisher>Yonsei University College of Medicine (KAMJE)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Coronary Stent Restenosis in Patients Treated With Cilostazol</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Douglas</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">R</forename><surname>Holmes</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.104.530097</idno>
		<idno type="PMID">16246948</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.104.530097" />
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<title level="j" type="abbrev">Circulation</title>
		<idno type="ISSN">0009-7322</idno>
		<idno type="ISSNe">1524-4539</idno>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="2826" to="2832" />
			<date type="published" when="2005-11-01" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (A randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1181" to="1188" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Comparison of Triple Antiplatelet Therapy and Dual Antiplatelet Therapy in Patients at High Risk of Restenosis After Drug–Eluting Stent Implantation (from the DECLARE-DIABETES and -LONG Trials)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kook-Jin</forename><surname>Chun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seong-Wook</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyun-Sook</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hak</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung-Cheol</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won-Jang</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jong-Young</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Duk-Woo</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheol</forename><forename type="middle">Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myeong-Ki</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyoung-Suk</forename><surname>Rhee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jei</forename><forename type="middle">Keon</forename><surname>Chae</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Ki</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Hyeong</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Hwan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Si</forename><forename type="middle">Wan</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jin-Ok</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">In-Whan</forename><surname>Seong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suh</forename><surname>Jon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoon</forename><forename type="middle">Haeng</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nae-Hee</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">June</forename><forename type="middle">Hong</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Jung</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2009.08.667</idno>
		<idno type="PMID">20102913</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Cardiology</title>
		<title level="j" type="abbrev">The American Journal of Cardiology</title>
		<idno type="ISSN">0002-9149</idno>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="168" to="173" />
			<date type="published" when="2010-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Comparison of Triple Versus Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation (from the DECLARE–Long Trial)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seong-Wook</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hak</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung-Cheol</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Duk-Woo</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheol</forename><forename type="middle">Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myeong-Ki</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyun-Sook</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Ki</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Hyeong</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Hwan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Si</forename><forename type="middle">Wan</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">In-Whan</forename><surname>Seong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoon</forename><forename type="middle">Haeng</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nae-Hee</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">June</forename><forename type="middle">Hong</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kook-Jin</forename><surname>Chun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Jung</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2007.05.032</idno>
		<idno type="PMID">17884371</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Cardiology</title>
		<title level="j" type="abbrev">The American Journal of Cardiology</title>
		<idno type="ISSN">0002-9149</idno>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1103" to="1108" />
			<date type="published" when="2007-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">A Randomized, Double-Blind, Multicenter Comparison Study of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seong-Wook</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hak</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung-Cheol</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Duk-Woo</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheol</forename><forename type="middle">Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Soo-Jin</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Jung</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Hwan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Si</forename><forename type="middle">Wan</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">In-Whan</forename><surname>Seong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nae-Hee</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoon</forename><forename type="middle">Haeng</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Won-Yong</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Jin</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Se-Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min-Su</forename><surname>Hyon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Duk-Won</forename><surname>Bang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Jin</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyun-Sook</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bong-Ki</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keun</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hoon-Ki</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chang-Bum</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sang-Gon</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min-Kyu</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyoung-Ha</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Woo-Jung</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2010.10.035</idno>
		<idno type="PMID">21392640</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American College of Cardiology</title>
		<title level="j" type="abbrev">Journal of the American College of Cardiology</title>
		<idno type="ISSN">0735-1097</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1264" to="1270" />
			<date type="published" when="2011-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yaling</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shouli</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Quanmin</forename><surname>Jing</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhulu</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dongmei</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qingfen</forename><surname>Shu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiuying</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2009.01.006</idno>
		<idno type="PMID">19332203</idno>
	</analytic>
	<monogr>
		<title level="j">American Heart Journal</title>
		<title level="j" type="abbrev">American Heart Journal</title>
		<idno type="ISSN">0002-8703</idno>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="733" to="739" />
			<date type="published" when="2009-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">The effects of post coronary stenting triple antiplatelet therapies on platelet functions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Intern Med</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="635" to="643" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Efficacy of Cilostazol in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Taohong</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huili</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huijun</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jianghua</forename><surname>Ren</surname></persName>
		</author>
		<idno type="DOI">10.1097/mjt.0b013e31825a3616</idno>
		<idno type="PMID">22975664</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Therapeutics</title>
		<title level="j" type="abbrev">American Journal of Therapeutics</title>
		<idno type="ISSN">1075-2765</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="151" to="153" />
			<date type="published" when="2013" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Effects of long-term triple anti-platelet therapy with low dose cilostazol after drug-eluting stent implantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Moon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Korean J Med</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="368" to="75" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Effects of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) on Platelet Aggregation and P-Selectin Expression in Patients Undergoing Coronary Artery Stent Implantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bong-Ki</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seong-Wook</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Se-Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Duk-Woo</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young-Hak</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheol</forename><forename type="middle">Whan</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Myeong-Ki</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jae-Joong</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seongsoo</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyun-Sook</forename><surname>Chi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Seung-Jung</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjcard.2007.03.070</idno>
		<idno type="PMID">17697815</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Cardiology</title>
		<title level="j" type="abbrev">The American Journal of Cardiology</title>
		<idno type="ISSN">0002-9149</idno>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="610" to="614" />
			<date type="published" when="2007-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D-W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-C</forename><surname>Yun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-K</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H-S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-K</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I-W</forename><surname>Seong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N-H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K-J</forename><surname>Chun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S-J</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.106.666396</idno>
		<idno type="PMID">17060388</idno>
		<ptr type="open-access" target="https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.106.666396" />
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<title level="j" type="abbrev">Circulation</title>
		<idno type="ISSN">0009-7322</idno>
		<idno type="ISSNe">1524-4539</idno>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="2148" to="2153" />
			<date type="published" when="2006-11-14" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting coronary arteries in non-stress/benestent disease) trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Kelbaek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Klovgaard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Helqvist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="2011" to="2027" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Baumgart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Klauss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Baer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="1627" to="1661" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Effects of antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Lu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Cardiovasc Dis</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="793" to="799" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Randomized Trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maurizio</forename><surname>Menichelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Antonio</forename><surname>Parma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edoardo</forename><surname>Pucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rosario</forename><surname>Fiorilli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francesco</forename><surname>De Felice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marco</forename><surname>Nazzaro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alessia</forename><surname>Giulivi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Domenico</forename><surname>Alborino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arianna</forename><surname>Azzellino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberto</forename><surname>Violini</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jacc.2007.01.081</idno>
		<idno type="PMID">17498576</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American College of Cardiology</title>
		<title level="j" type="abbrev">Journal of the American College of Cardiology</title>
		<idno type="ISSN">0735-1097</idno>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1924" to="1930" />
			<date type="published" when="2007-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Clinical outcome of patients with diabetes mellitus and chronic total occlusion after drug-eluting stenting followed by cilostazol treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Suh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">S</forename><surname>Seo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eurointervention</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
	<note>Supp E</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Sirolimus-eluting vs. uncoated stents for prevention of restenosis in small coronary arteries: A randomized trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Ardissino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Cavallini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Bramucci</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.accreview.2005.02.035</idno>
	</analytic>
	<monogr>
		<title level="j">ACC Current Journal Review</title>
		<title level="j" type="abbrev">ACC Current Journal Review</title>
		<idno type="ISSN">1062-1458</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="41" to="42" />
			<date type="published" when="2005-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Menozzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Solinas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ortolani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Repetto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Saia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Piovaccari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Manari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Magagnini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Vignali</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Bonizzoni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">A</forename><surname>Merlini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Cavallini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Ardissino</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehp224</idno>
		<idno type="PMID">19508994</idno>
		<idno type="ark">ark:/67375/HXZ-6T258PW0-M</idno>
		<idno type="istexId">F2ABC8FED3B01FAD5395485A26DEEE825FE52338</idno>
		<ptr type="open-access" target="https://academic.oup.com/eurheartj/article-pdf/30/17/2095/1360364/ehp224.pdf" />
	</analytic>
	<monogr>
		<title level="j">European Heart Journal</title>
		<title level="j" type="abbrev">European Heart Journal</title>
		<idno type="ISSN">0195-668X</idno>
		<idno type="ISSNe">1522-9645</idno>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2095" to="2101" />
			<date type="published" when="2009-06-09" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">W</forename><surname>Moses</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><forename type="middle">B</forename><surname>Leon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">J</forename><surname>Popma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">J</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charles</forename><surname>O'shaughnessy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronald</forename><forename type="middle">P</forename><surname>Caputo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dean</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">O</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paul</forename><forename type="middle">S</forename><surname>Teirstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Judith</forename><forename type="middle">L</forename><surname>Jaeger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">E</forename><surname>Kuntz</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa035071</idno>
		<idno type="PMID">14523139</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/b51e/6bf2f9dc38f76c55ea2caa185b11833901ee.pdf" />
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1315" to="1323" />
			<date type="published" when="2003-10-02" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Effect of cilostazol on restenosis in elderly patients with coronary bare-metal stents implantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Z</forename><surname>Lv</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin J Geriatr</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="537" to="78" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
